Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market to Reach US$ 1959.8 Mn by 2026, Favoured by Grifols’ Worldwide Promotion for AlfaCare, Says Fortune Business Insights Pune, July 12, 2019 (GLOBE NEWSWIRE) -- The global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market has been boosted by recent FDA approval for Prolastin-C. According to a report...